Outlook Therapeutics' ONS-5010/LYTENAVA receives positive CHMP opinion for wet AMD treatment, shares surge 40%.
Outlook Therapeutics (OTLK) shares surge over 40% on Friday after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for ONS-5010/LYTENAVA (bevacizumab gamma), intended to treat wet age-related macular degeneration (wet AMD) in the EU. The positive opinion serves as a basis for potential authorization from the European Commission within 67 days.
March 22, 2024
4 Articles